---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117172"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:09:46.619237+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eyenovia reports Q3 2022 net loss of $7.3M; MicroLine VISION-2 Phase 3 trial meets primary endpoint

## Summary
- Net loss of $7.3M ($0.21 per share) vs $5.6M loss in Q3 2021; cash $25.3M (incl. $7.9M restricted) as of Sep 30, 2022.
- VISION-2 trial achieved primary endpoint: statistically significant ≥15-letter DCNVA improvement at 2 hours; FDA meeting planned.
- Michael Rowe appointed CEO (former COO) and to Board of Directors; manufacturing facility in Redwood City, CA now operational.
- Arctic Vision Phase 3 trial of MicroLine in China enrolling patients; expects completion in late 2023.
- Collaboration with Bausch+Lomb and Optejet out-licensing progress noted; company evaluating additional partnerships.

## SEC filing metadata
- accession: 0001104659-22-117172
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/0001104659-22-117172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/tm2230140d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117172
- JSON: https://secwatch.observer/filing/0001104659-22-117172.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117172.txt

## Key facts
- Earnings Releases
  HYPERION DEFI, INC. reported third quarter ended September 30, 2022 results: net income net loss was approximately $(7.3) million, or $(0.21) per share, EPS $(0.21) per share.
  - Period: third quarter ended September 30, 2022
  - Net income: net loss was approximately $(7.3) million, or $(0.21) per share
  - EPS: $(0.21) per share
  - Result: reported results
  source text: Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/0001104659-22-117172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.